January 2026 in “Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna)”
This study observed that baricitinib led to significant hair regrowth and improved psychological well-being in severe alopecia areata patients over 48 weeks, with 63.2% achieving a SALT score of ≤20.
September 2025 in “Journal of the European Academy of Dermatology and Venereology”
This real-world study found that baricitinib 4 mg daily was effective in promoting hair regrowth and improving psychological well-being in Italian adults with severe alopecia areata over 48 weeks, with 63.2% of patients achieving significant hair recovery and 9.4% experiencing adverse events.
September 2024 in “Journal of the European Academy of Dermatology and Venereology”
This study found that baricitinib significantly reduced hair loss in patients with severe alopecia areata, decreasing the mean SALT score from 96.6 to 48 over 24 weeks, with no patients dropping out and only mild adverse events in 12.7% of participants.